Mimedx Group, Inc · NASDAQ:MDXG
Mimedx — Investor Presentation (February 2025)
26 slides from Mimedx's investor presentation, Feb 27, 2025
Slide 1: February 2025 Investor Presentation
February 2025 Investor Presentation
Slide 2: Disclaimer & Cautionary Statements
Disclaimer & Cautionary Statements This presentation includes forward-looking statements. Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual results may differ materially from those set forth
Slide 3: A Pioneer and Leader Focused on Helping Humans Heal
A Pioneer and Leader Focused on Helping Humans Heal Investor Presentation – February 2025 3 Over a decade of experience helping clinicians manage chronic and other hard-to-heal wounds Leading the industry with innovative products and robust supporting clinical data Poised to capitalize on favorable
Slide 4: Increasing Awareness of Massive Potential for Placental Tissue
4Investor Presentation – February 2025 “Research has found placenta-derived grafts can reduce pain and inflammation, heal burns, prevent the formation of scar tissue and adhesions around surgical sites and even restore vision. They’re also gaining popularity as a treatment for the widespread issue o
Slide 5: Addressing a Large and Unmet Need for Healing Solutions
Addressing a Large and Unmet Need for Healing Solutions Investor Presentation – February 2025 5 Favorable Demographic Trends Increasing Clinical Evidence Expanding Potential For Products 1) Sen CK. Human Wound and Its Burden: Updated 2022 Compendium of Estimates. Adv Wound Care (New Rochelle). 2023;
Slide 6: The Patient Journey in Wound Care
The Patient Journey in Wound Care 6Investor Presentation – February 2025 MIMEDX products are available in all settings where patients receive care… Private Office Home Health Mobile Health Nursing Facility Assisted Living Facility Wound Care Clinic Hospital Outpatient Hospital Inpatient …and other c
Slide 7: Expansive Donor Network & IP Power
Expansive Donor Network & IP Power Our Product Offering 7Investor Presentation – February 2025 National Network of Birthing Center Partners Ample Placental Supply and Manufacturing Capabilities to Support Continued Growth and Industry Demand Expectant Mothers Introduced to Donation Program Consent f
Slide 8: The Most Comprehensive End-to-End Product Ecosystem
The Most Comprehensive End-to-End Product Ecosystem 8Investor Presentation – February 2025 The most studied portfolio of placental products with 50+ clinical & scientific publications and over 300 million payer covered lives. New product innovations leading to untapped opportunities for growth, incl
Slide 9: Commercial Scale, Leverage & Extensive Reach
Commercial Scale, Leverage & Extensive Reach 9Investor Presentation – February 2025 Over 75 agencies with 200+ agents nationwide Robust corporate support network Over 200 direct sales professionals nationwide Extensive commercial coverage with over 300 million payer lives covered Experience selling
Slide 10: Highlights from Our Expanding Product Portfolio
Highlights from Our Expanding Product Portfolio 10Investor Presentation – February 2025 Flagship Wound Allograft Growing Surgical Offering Expanding into Xenografts
Slide 11: Large Wound Care Business with Growing Surgical Footprint
Large Wound Care Business with Growing Surgical Footprint 11Investor Presentation – February 2025 $0 $50,000 $100,000 $150,000 $200,000 $250,000 $0 00 s 2024 Surgical Performance 2023 2024 $0 $50,000 $100,000 $150,000 $200,000 $250,000 $0 00 s 2024 Wound Performance 2023 2024 66% 34% 2024 Sales Mix
Slide 12: Building Library of Evidence for Surgical Applications
Building Library of Evidence for Surgical Applications 12Investor Presentation – February 2025 Recent Publications Showcase Breadth of Potential Use Cases for MIMEDX Products in Surgery Neuro Orthopedic Gastrointestinal Mohs Plastic OB/GYN Foot & Ankle Vascular Transplant Cranioplasty Procedures wit
Slide 13: Studies in Process Focused on Significant Surgical Opportunities
Studies in Process Focused on Significant Surgical Opportunities 13Investor Presentation – February 2025 EPIFIX used in Mohs procedures associated with avoidance of postoperative complications and ancillary procedures, compared to patients treated with standard of care. Accepted for Publication Seek
Slide 14: Evolving Strategic Priorities Heading into 2025
Evolving Strategic Priorities Heading into 2025 Investor Presentation – February 2025 14 Innovate & Diversify Product Portfolio to Maximize Growth Develop & Deploy Programs to Expand Surgical Footprint Enhance Customer Intimacy Continue introducing new products for our served markets Accelerate OUS
Slide 15: CMS Reimbursement Overhaul Still Expected in 2025
CMS Reimbursement Overhaul Still Expected in 2025 Investor Presentation – February 2025 15 February 12 implementation date pushed out to April 13 following new administration executive order Feedback from outside advisors & activity from new administration suggests further delays are highly unlikely
Slide 16: Financial Highlights
Financial Highlights 16Investor Presentation – February 2025 2024 Net Sales $349MM +9% year-over-year 2024 Adjusted Gross Margin 84% 2024 Adjusted EBITDA1 $77MM 22% of net sales 2024 GAAP Net Income $42MM Cash Balance $104MM +$22MM vs. Q4:23 2024 Free Cash Flow $65MM Strong & improving financial pro
Slide 17: Experienced, Skillful Leadership Team Executing Strategy
Experienced, Skillful Leadership Team Executing Strategy 17Investor Presentation – February 2025 Joe Capper Chief Executive Officer Ricci Whitlow Chief Operating Officer Matt Notarianni Head of IR Kate Surdez Chief Human Resource Officer Butch Hulse Chief Administrative Officer & General Counsel Joh
Slide 18: Conclusion
Conclusion Investor Presentation – February 2025 18 1 2 3 4 Large & expanding addressable markets Maturing reimbursement & regulatory landscape 5 Competitive advantage with defensible IP and proprietary technology Strong & improving financial profile & balance sheet Experienced & skillful leadership
Slide 19: Appendix
—_~ MIMEDX Appendix 19°
Slide 20: Reconciliation of Non-GAAP Measures
Reconciliation of Non-GAAP Measures In addition to our GAAP results, we provide certain non-GAAP measures including Adjusted EBITDA, related margins, Free Cash Flow, Adjusted Gross Profit, Adjusted Gross Margin and Adjusted Net Income. • Adjusted EBITDA consists of GAAP net income excluding: (i) dep
Slide 21: Reconciliation of Non-GAAP Measures (cont.)
Reconciliation of Non-GAAP Measures (cont.) • Each of the adjustments to reconcile Adjusted Net Income to GAAP net income affect individual financial statement captions which are reflected in our consolidated statements of operations, including gross profit. Adjusted Gross Profit is therefore define
Slide 22: Adjusted Gross Profit & Adjusted Gross Profit Margin
Adjusted Gross Profit & Adjusted Gross Profit Margin 22 Three Months Ended Twelve Months Ended Amounts (in millions) December 31, 2024 December 31, 2023 December 31, 2024 December 31, 2023 GAAP gross profit $ 76.0 $ 73.0 $ 288.8 $ 266.8 Amortization of acquisition-related intangible assets 2.2 — 3.0
Slide 23: Adjusted EBITDA - QTD
Adjusted EBITDA - QTD 23 Amounts (in millions) for the three months ended December 31, 2024 December 31, 2023 Net income $ 7.4 $ 53.5 Depreciation expense 0.6 0.6 Amortization of intangible assets 2.4 0.2 Interest (income) expense, net (0.4) 1.6 Income tax provision 3.8 (40.3) Stock-based compensati
Slide 24: Adjusted EBITDA - YTD
Adjusted EBITDA - YTD 24 Amounts (in millions) for the twelve months ended December 31, 2024 December 31, 2023 Net income $ 42.4 $ 58.2 Depreciation expense 2.3 2.7 Amortization of intangible assets 3.8 0.8 Interest expense, net 1.0 6.5 Income tax provision 15.3 (39.8) Stock-based compensation expen
Slide 25: Adjusted Net Income and Adjusted EPS - QTD
Adjusted Net Income and Adjusted EPS - QTD 25 Amounts (in millions) for the three months ended December 31, 2024 December 31, 2023 Net income - GAAP $ 7.4 $ 53.5 Investigation, restatement and related expense — 0.5 Amortization of acquisition-related intangible assets 2.2 — Disbanding of Regenerativ
Slide 26: Adjusted Net Income and Adjusted EPS - YTD
Adjusted Net Income and Adjusted EPS - YTD 26 Amounts (in millions) for the twelve months ended December 31, 2024 December 31, 2023 Net income - GAAP $ 42.4 $ 58.2 Loss on extinguishment of debt 1.4 — Investigation, restatement and related expense (8.7) 5.2 Amortization of acquisition-related intang